Concepedia

Author

Charles Herbaux

Centre Hospitalier Universitaire de LilleORCID

Also Known As

C Herbaux, C Herbaux (7760396), C. Herbaux, Charles Herbaux, Charles Jean Yvon Herbaux, Herbaux, C., Herbaux, C. (Charles), Herbaux, Charles

302

Publications

4.8K

Citations

33

H-Index

61

Concepts

All Affiliations

Centre Hospitalier Universitaire de LilleInsermAssistance Publique – Hôpitaux de ParisUniversité de LilleCentre Hospitalier Universitaire de Montpellier
CH

About

Charles Herbaux is an author at Centre Hospitalier Universitaire de Lille specializing in medicine, immunology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

14

866

2

Health Sciences

6

6

528

3

Cell Biology

2

2

31

4

Cellular Therapies

1

1

43

5

Genetic Medicine

1

1

19

Charles Herbaux

×

61

Publications

4.1K

Citations

31

H-Index

YearCitations

The MLL recombinome of acute leukemias in 2013

Claus Meyer, Jörg Hofmann, Thomas Burmeister,

Leukemia

2013

506

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

Meletios Α. Dimopoulos, Alessandra Tedeschi, Judith Trotman,

New England Journal of Medicine

2018

342

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

David Ghez, Anne Calleja, Caroline Protin,

Blood

2018

288

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

Nicolas Delanoy, Jean‐Marie Michot, Thibault Comont,

The Lancet Haematology

2018

269

MYD88 L265P mutation in Waldenstrom macroglobulinemia

Stéphanie Poulain, Christophe Roumier, Audrey Decambron,

Blood

2013

228

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

Charles Herbaux, Jordan Gauthier, Pauline Brice,

Blood

2017

215

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

Steven Le Gouill, Franck Morschhauser, David Chiron,

Blood

2020

127

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group

Emmanuelle Tchernonog, P. Faurie, Paul Coppo,

Annals of Oncology

2016

124

Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia

Stéphanie Poulain, Christophe Roumier, Aurélie Venet-Caillault,

Clinical Cancer Research

2015

120

Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

Cédric Rossi, Julia Gilhodes, Marie Maerevoet,

American Journal of Hematology

2018

116

Page 1